Answers are grounded in this paper and cite their sources.
The efficacy of antineoplastic chemotherapies with anthracyclines or oxaliplatin relies on the induction of immunogenic cell death, thus provoking an anticancer immune response. Recently, we observed that overexpression of CD39, an ATP-degrading enzyme expressed on the cell surface, abolishes the immunogenicity of cell death, thus rendering cancers resistant against chemotherapy.
No takes yet. Share an insight, caveat, or question.
Michaud et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: